We are live on ! Find out more
TOVX icon

Theriva Biologics
TOVX

22 hedge funds and large institutions have $1.93M invested in Theriva Biologics in 2018 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.08% more ownership

Funds ownership: 0% → 0.08% (+0.08%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

52% less funds holding

Funds holding: 46 → 22 (-24)

74% less capital invested

Capital invested by funds: $7.28M → $1.93M (-$5.35M)

89% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 27

Holders
22
Holders Change
-24
Holders Change %
-52.17%
% of All Funds
0.5%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
4
Closed
27
Calls
$13.6M
Puts
–
Net Calls
+$13.6M
Net Calls Change
+$12.4M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$200K
2
VF
Virtu Financial
New York
+$149K
3
Jane Street
Jane Street
New York
+$82.9K
4
TSS
Two Sigma Securities
New York
+$42K
5
MAM
Meeder Asset Management
Ohio
+$9.95K

Top Sellers

Rank Fund Capital Flow
1
MP
MSD Partners
New York
-$984K
2
William Blair & Company
William Blair & Company
Illinois
-$529K
3
Millennium Management
Millennium Management
New York
-$48K
4
Northern Trust
Northern Trust
Illinois
-$41K
5
Creative Planning
Creative Planning
Kansas
-$40K
Name Holding Trade Value Shares
Change 		Change in
Stake
TS
1
Third Security
Virginia
$983K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$352K +$7.74K +7 +1%
Renaissance Technologies
3
Renaissance Technologies
New York
$118K +$200K +181 New
6CM
4
683 Capital Management
New York
$111K – – –
BlackRock
5
BlackRock
New York
$100K – – –
VF
6
Virtu Financial
New York
$88K +$149K +135 New
Jane Street
7
Jane Street
New York
$49K +$82.9K +75 New
Geode Capital Management
8
Geode Capital Management
Massachusetts
$45K – – –
TSS
9
Two Sigma Securities
New York
$29K +$42K +38 +543%
LTFS
10
Ladenburg Thalmann Financial Services
Florida
$13K – – –
IA
11
IFP Advisors
Florida
$12K – – –
SAM
12
Scopus Asset Management
New York
$7K – – –
MAM
13
Meeder Asset Management
Ohio
$7K +$9.95K +9 +900%
FIA
14
FNY Investment Advisers
New York
$5K – – –
UBS Group
15
UBS Group
Switzerland
$2K -$17.7K -16 -84%
Morgan Stanley
16
Morgan Stanley
New York
$1K -$2.21K -2 -50%
Bank of America
17
Bank of America
North Carolina
$1K -$1.1K -1 -33%
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$1K -$1.1K -1 -33%
Bank of Montreal
19
Bank of Montreal
Ontario, Canada
$1K – – –
IP
20
Intellectus Partners
California
$1K – – –
VFA
21
Valeo Financial Advisors
Indiana
$1K – – –
BNP Paribas Financial Markets
22
BNP Paribas Financial Markets
France
$3 – – –
MP
23
MSD Partners
New York
– -$984K -471 Closed
William Blair & Company
24
William Blair & Company
Illinois
– -$529K -253 Closed
Millennium Management
25
Millennium Management
New York
– -$48K -23 Closed
1
2

TOVX Hedge Fund Activity: Q3 2018 in Review

22 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Theriva Biologics (TOVX) for Q3 2018, worth a combined $1.93M — down 74% from $7.28M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of TOVX and 3 opened new positions — a net loss of 24 holders — while 4 trimmed existing stakes and 3 added.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $200K. The largest seller was MSD Partners, exiting entirely with an estimated $984K sold.

  • 22 institutional investors held Theriva Biologics (TOVX) as of Q3 2018, down from 46 in Q2 2018.
  • Funds reported $1.93M of Theriva Biologics stock for Q3 2018, down 74% quarter-over-quarter.
  • 3 funds opened new Theriva Biologics positions in Q3 2018 and 27 closed out, a net change of -24 holders.
  • The largest Theriva Biologics buyer in Q3 2018 was Renaissance Technologies, an estimated $200K added.
  • The largest Theriva Biologics seller in Q3 2018 was MSD Partners, an estimated $984K sold.

Based on aggregated 13F filings for Q3 2018.